title: Treatment of Relapsed/Refractory Multiple Myeloma.
abstract: Survival outcomes of patients with Multiple Myeloma (MM) have improved over the last decade due to the introduction of novel agents such as the immunomodulatory drugs thalidomide, lenalidomide (Len) and pomalidomide, and the proteasome inhibitors bortezomib (BTZ) and carfilzomib [1, 2]. However, despite these major advances, MM remains largely incurable and almost all patients relapse and require additional therapy [3]. The successful introduction of next generation novel agents including oral proteasome inhibitors, deacetylase inhibitors, and especially monoclonal antibodies as part of immunotherapy promises to further improve outcome.
authors.affiliation: Southern Alberta Cancer Research Institute, University of Calgary, Calgary, AB, Canada.
authors.forename: Paola
authors.initials: P
authors.lastname: Neri
authors.affiliation: Southern Alberta Cancer Research Institute, University of Calgary, Calgary, AB, Canada.
authors.forename: Nizar J
authors.initials: NJ
authors.lastname: Bahlis
authors.affiliation: Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Claudia
authors.initials: C
authors.lastname: Paba-Prada
authors.affiliation: Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA. paul_richardson@dfci.harvard.edu.
authors.forename: Paul
authors.initials: P
authors.lastname: Richardson
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D016879:Salvage Therapy / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents
keywords: Combination therapy; Novel agents; Relapsed and refractory multiple myeloma